Scientific Research An Academic Publisher
OPEN ACCESS
Add your e-mail address to receive free newsletters from SCIRP.
Select Journal AA AAD AAR AASoci AAST ABB ABC ABCR ACES ACS ACT AD ADR AE AER AHS AID AiM AIT AJAC AJC AJCC AJCM AJIBM AJMB AJOR AJPS ALAMT ALC ALS AM AMI AMPC ANP APD APE APM ARS ARSci AS ASM BLR CC CE CellBio ChnStd CM CMB CN CRCM CS CSTA CUS CWEEE Detection EMAE ENG EPE ETSN FMAR FNS GEP GIS GM Graphene GSC Health IB ICA IIM IJAA IJAMSC IJCCE IJCM IJCNS IJG IJIDS IJIS IJMNTA IJMPCERO IJNM IJOC IJOHNS InfraMatics JACEN JAMP JASMI JBBS JBCPR JBiSE JBM JBNB JBPC JCC JCDSA JCPT JCT JDAIP JDM JEAS JECTC JEMAA JEP JFCMV JFRM JGIS JHEPGC JHRSS JIBTVA JILSA JIS JMF JMGBND JMMCE JMP JPEE JQIS JSBS JSEA JSEMAT JSIP JSS JSSM JST JTR JTST JTTs JWARP LCE MC ME MI MME MNSMS MPS MR MRC MRI MSA MSCE NJGC NM NR NS OALib OALibJ ODEM OJA OJAB OJAcct OJAnes OJAP OJApo OJAppS OJAPr OJAS OJBD OJBIPHY OJBM OJC OJCB OJCD OJCE OJCM OJD OJDer OJDM OJE OJEE OJEM OJEMD OJEpi OJER OJF OJFD OJG OJGas OJGen OJI OJIC OJIM OJINM OJL OJM OJMC OJMetal OJMH OJMI OJMIP OJML OJMM OJMN OJMP OJMS OJMSi OJN OJNeph OJO OJOG OJOGas OJOp OJOph OJOPM OJOTS OJPathology OJPC OJPChem OJPed OJPM OJPP OJPS OJPsych OJRA OJRad OJRD OJRM OJS OJSS OJSST OJST OJSTA OJTR OJTS OJU OJVM OPJ POS PP PST PSYCH SAR SCD SGRE SM SN SNL Soft SS TEL TI UOAJ VP WET WJA WJCD WJCMP WJCS WJET WJM WJNS WJNSE WJNST WJV WSN YM
More>>
Markman, M. (2009) An Update on the Use of Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. Cancer Journal, 15, 105-109. http://dx.doi.org/10.1097/PPO.0b013e31819e31f2
has been cited by the following article:
TITLE: Current Possible Drug Therapies for Ovarian Cancer
AUTHORS: Jungyeob Seoung, Young-Han Park, Chaechun Rhim, Sungju Kim
KEYWORDS: Ovarian Cancer, Intraperitoneal Chemotherapy, Targeting Therapy
JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.13, November 7, 2014
ABSTRACT: Ovarian cancer is the most aggressive gynecologic cancer of the heterogenous phenotypes. Development of the new chemotherapeutic agents and drug delivery mode makes better outcomes for patient treatments. Optimal cytoreductive therapy followed by molecular targeting therapy, intraperitoneal chemotherapy and dose dense chemotherapy is a hot therapeutic concept in ovarian cancers. In our review, we will introduce recent therapeutic advances in epithelial ovarian cancer patients.
Related Articles:
Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Carcinomatosis: Is HIPEC the Only Answer?
Ka-On Lam, Betty Tsz-Ting Law, Simon Ying-Kit Law, Dora Lai-Wan Kwong
DOI: 10.4236/mc.2014.32003 5,495 Downloads 8,134 Views Citations
Pub. Date: January 4, 2015
Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis
Andrea Messori, Valeria Fadda, Dario Maratea, Sabrina Trippoli
DOI: 10.4236/jct.2013.47145 4,269 Downloads 5,360 Views Citations
Pub. Date: September 4, 2013
Quality of Life in Ovarian-Cancer Patients Receiving Chemotherapy
Tohmina Akhter, Shahana Pervin, Annekathryn Goodman
DOI: 10.4236/jct.2020.1111059 137 Downloads 350 Views Citations
Pub. Date: November 19, 2020
Effect of Dioscorea Pills on Immunity of Mice Receiving Chemotherapy for Ovarian Cancer
Yiming Tang, Huijun Xu
DOI: 10.4236/oalib.1105247 201 Downloads 450 Views Citations
Pub. Date: February 28, 2019
Dermatomyositis Associated with Docetaxel Use in the Treatment for Ovarian Cancer
Yuta Ito, Yuko Hamada, Keiko Katayama, Hirokazu Uno, Tokio Nakada
DOI: 10.4236/crcm.2017.610031 572 Downloads 977 Views Citations
Pub. Date: October 23, 2017
